Dr. Galsky Discusses Combination Immunotherapy in Bladder Cancer

Video

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses combination immunotherapy in the treatment of patients with bladder cancer.

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses combination immunotherapy in the treatment of patients with bladder cancer.

Galsky says that a big question in the platinum-resistant setting of metastatic bladder cancer is the use of combination immunotherapy. Data from other solid tumors such as melanoma, kidney cancer, and lung cancer, have shown that combination immunotherapy might increase response rates compared with single-agent therapy. These responses also tend to be quite durable, Galsky explains.

The CheckMate-901 study (NCT03036098) is currently exploring the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) or standard of care versus standard of care alone in patients with previously untreated unresectable or metastatic bladder cancer. Standard of care in this population is a cisplatin-containing regimen. This phase III, randomized, open-label study is a more complex randomization, Galsky says, as it is handled differently based on whether patients are cisplatin-eligible or cisplatin-ineligible.

The primary endpoint of CheckMate-901 is based on the cisplatin-ineligible population, who are being randomized to either nivolumab plus ipilimumab or standard of care cisplatin.

Related Videos
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD